Supplementary Figure 7 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i>^LOF<i>/BRAF</i>^MUT Melanoma through PI3K and IGF1R Inhibition

Abstract

&lt;p&gt;Concomitant inhibition of PI3Kβ, IGF1R and MAPK signaling are leading to induction of cell death. A) Effects of treatment with the indicated inhibitors as single-agents in RVH-421 were evaluated by immunoblotting using phospho-specific or total target protein antibodies. B) Fractions of living (A-/PI-), necrotic (A-/PI+), early (A+/PI-) and late (A+/PI+) apoptotic cells was measured upon treatment of A101D and C32 with the indicated compounds for 72h. Data are represented as mean ({plus minus}SD) of triplicates. PI3Kβi=rac-KIN-193, PI3Kαi=BYL719, IGF1Ri=AEW541, panPI3Ki=GDC0941, BRAFi=LGX818, MEKi=MEK162&lt;/p&gt;